Evidence map›Paper›PMID 29740535›Full record

ArticleFrontiers in oncology2018

Enhancing the Therapeutic Efficacy of Cancer Treatment With Cannabinoids.

Sayeda Yasmin-Karim, Michele Moreau, Romy Mueller, Neeharika Sinha, Raymond Dabney, Allen Herman, Wilfred Ngwa

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 40 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Cannabinoids in the landscape of cancer.Journal of cancer research and clinical oncology · 2021
    Review
  15. Review
  16. OptimizingFrontiers in oncology · 2021
    Article
  17. Cannabinoids in Medicine: Cancer, Immunity, and Microbial Diseases.International journal of molecular sciences · 2020
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Sayeda Yasmin-KarimRadiation Oncology, Brigham and Women's Hospital, Boston, MA, United States.
Michele MoreauDana-Farber Cancer Institute, Boston, MA, United States.
Romy MuellerRadiation Oncology, Brigham and Women's Hospital, Boston, MA, United States.
Neeharika SinhaRadiation Oncology, Brigham and Women's Hospital, Boston, MA, United States.
Raymond DabneyCannabis Science, Inc., Irvine, CA, United States.
Allen HermanCannabis Science, Inc., Irvine, CA, United States.
Wilfred NgwaRadiation Oncology, Brigham and Women's Hospital, Boston, MA, United States.
Brigham and Women's Hospital · USUniversity of Massachusetts Lowell · USDana-Farber Cancer Institute · US

Funding

Primers: Combining Radiotherapy and Immunotherapy using next genertaion radiotherapy biomaterialsR21CA205094 · NCI · DANA-FARBER CANCER INST · PI NGWA, WILFRED · 2017 to 2018
$421k
6 · The paper itself

Abstract

Over the years, many

Indexed as

biomaterialscancercannabinoids or endocannabinoidsradiotherapysurvival

Identifiers

PMID29740535
PMCPMC5928848
OpenAlexW2801807973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.